Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

DDI Between BI Empagliflozin (10773) and Verapamil

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Verapamil

First Posted Date: 2011-01-13

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT01276301

Locations: 🇩🇪
1245.43.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin/Pioglitazone
Drug: Linagliptin + Pioglitazone

First Posted Date: 2011-01-13

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT01276327

Locations: 🇩🇪
1264.14.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Vinorelbine 25 mg/m2 weekly
Drug: Afatinib 40mg once daily (OD)
Drug: Paclitaxel 80 mg/m2 weekly

First Posted Date: 2011-01-07

Last Posted Date: 2019-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 74

Registration Number: NCT01271725

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇮🇳
Curie Manavata Cancer Centre, Maharashtra, India
🇷🇺
St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan", Kazan, Russian Federation

and more 24 locations

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: tiotropium Respimat low dose
Drug: tiotropium Respimat high dose
Drug: placebo Respimat

First Posted Date: 2010-12-09

Last Posted Date: 2014-09-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 398

Registration Number: NCT01257230

Locations: 🇺🇸
205.444.01005 Boehringer Ingelheim Investigational Site, Columbia, Missouri, United States
🇺🇦
205.444.38004 Boehringer Ingelheim Investigational Site, Kiev, Ukraine
🇺🇦
205.444.38010 Boehringer Ingelheim Investigational Site, Zaporizhya, Ukraine

and more 63 locations

A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Completed

Conditions: Neoplasms

Interventions: Drug: Afatinib
Drug: docetaxel
Drug: gemcitabine

First Posted Date: 2010-12-02

Last Posted Date: 2016-05-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 94

Registration Number: NCT01251653

Locations: 🇫🇷
1200.93.33002 Boehringer Ingelheim Investigational Site, Dijon, France
🇫🇷
1200.93.33001 Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France
🇫🇷
1200.93.33003 Boehringer Ingelheim Investigational Site, Toulouse, France

A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773

First Posted Date: 2010-11-25

Last Posted Date: 2014-09-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 91

Registration Number: NCT01248364

Locations: 🇩🇪
1245.39.49002 Boehringer Ingelheim Investigational Site, Neuss, Germany
🇦🇹
1245.39.43001 Boehringer Ingelheim Investigational Site, Graz, Austria
🇮🇹
1245.39.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: linagliptin
Drug: glimepiride
Drug: linagliptin placebo
Drug: glimepiride placebo

First Posted Date: 2010-11-18

Last Posted Date: 2020-01-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6103

Registration Number: NCT01243424

Locations: 🇺🇸
PMI Health Research Group, Atlanta, Georgia, United States
🇺🇸
North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸
Matrix Research Institute, Tustin, California, United States

and more 604 locations

A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy

Completed

Conditions: Hypertension

Interventions: Drug: Twynsta tablet

First Posted Date: 2010-11-18

Last Posted Date: 2018-10-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 674

Registration Number: NCT01243268

Locations: 🇰🇷
NISND Center, One Or Multiple Sites, Korea, Republic of

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773 (Final Formulation)
Drug: BI 10773 XX (Trial Formulation 2)

First Posted Date: 2010-11-16

Last Posted Date: 2014-06-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01242176

Locations: 🇩🇪
1245.51.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

Phase 1

Completed

Conditions: Cardiovascular Diseases
Kidney Failure, Chronic

Interventions: Drug: Dabigatran etexilate

First Posted Date: 2010-11-16

Last Posted Date: 2014-04-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT01241539

Locations: 🇩🇪
1160.121.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy